Premium
Psoriasis and non‐alcoholic fatty liver disease
Author(s) -
Wenk KS,
Arrington KC,
Ehrlich A
Publication year - 2011
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2010.03841.x
Subject(s) - medicine , adipokine , psoriasis , fatty liver , proinflammatory cytokine , insulin resistance , metabolic syndrome , disease , inflammation , population , pathophysiology , obesity , alcoholic liver disease , immunology , cirrhosis , environmental health
Several recent studies have found an increased prevalence of non‐alcoholic fatty liver disease within psoriasis patients. The exact pathophysiological mechanisms behind these observations are unclear, but are likely related to the high prevalence of obesity and metabolic syndrome within this patient population. Chronic inflammation, mediated by either proinflammatory adipokines or skin‐derived cytokines, may contribute to fatty liver disease development by increasing insulin resistance which in turn promotes hepatic lipid accumulation. These same adipokines in addition to hepatic cytokines may act on the skin to influence psoriasis disease severity.